Loading organizations...

§ Private Profile · Durham, NC, USA
AI-driven drug discovery platform for lethal diseases.
Ten63 Therapeutics has raised $61.0M across 2 funding rounds.
Key people at Ten63 Therapeutics.
Ten63 Therapeutics has raised $61.0M in total across 2 funding rounds.
Ten63 Therapeutics develops small molecule therapeutics for challenging disease targets, primarily in oncology. The company employs its proprietary BEYOND platform, integrating artificial intelligence with physics-based models. This computational approach efficiently explores vast chemical spaces to design drug candidates against historically undruggable proteins, accelerating the development of effective, durable therapies.
The company's foundation rests on over two decades of academic research in protein design. Co-founded by CEO Marcel Frenkel and Professor Brian Kuhlman of the University of North Carolina at Chapel Hill, their insight was applying advanced computational methods to rationally design small molecule drugs. This enabled the pursuit of previously intractable disease mechanisms.
Ten63 focuses on creating first- and best-in-class therapeutics for patients with severe, difficult-to-treat cancers and other life-threatening conditions. By targeting previously undruggable mechanisms, the company aims to significantly impact patient care. Its vision is to pioneer a new era of drug discovery, expanding therapeutic options and delivering improved health outcomes.
Ten63 Therapeutics is a biotech startup founded in 2018 that develops AI-driven computational chemistry platforms to design potent therapeutics against "undruggable" targets—medically validated proteins previously inaccessible to traditional drugs.[1][2][3] Their core product, the BEYOND platform, uses machine learning (ML), proprietary physical models, and superlinear search algorithms to screen trillions of molecules, predict tumor mutations years in advance, and create drugs resilient to evolutionary changes in diseases like cancer.[1][3][5] Serving patients with hard-to-treat conditions, Ten63 addresses the limitation that only 2-4% of drug targets are both druggable and disease-modifying, enabling in silico drug design based on molecular movement to improve human health.[1][2]
With 2-10 employees and undisclosed funding, the company is headquartered in Durham, North Carolina, and has early traction through accelerators like IndieBio and SOSV, positioning it for growth in precision medicine.[1][2][3]
Ten63 Therapeutics was founded in 2018, emerging from the need to conquer undruggable targets in drug discovery using advanced computational methods.[1][2][3] While specific founders are not detailed in available sources, the company's inception aligns with breakthroughs in AI and ML for biotech, as highlighted in IndieBio's portfolio where it was accelerated as an early-stage biotech innovator.[1]
Early pivotal moments include developing the BEYOND platform, which for the first time enables prediction of tumor mutations during drug design, allowing proactive therapeutics against future resistance—a leap beyond conventional methods.[1][3] Backed by SOSV, Ten63 gained visibility in the startup ecosystem, focusing from the outset on mathematically guaranteed algorithms combined with low-residual ML to explore vast chemical spaces.[3]
Ten63 rides the wave of AI-powered drug discovery, a trend exploding as computational tools democratize access to complex biology amid rising cancer resistance and undruggable target challenges.[1][2][3] Timing is ideal post-2018, with ML maturity enabling trillion-scale screening and physical models refining predictions, fueled by market forces like biotech funding surges and demands for mutation-resilient therapies.[1][3]
By influencing the ecosystem through accelerators like IndieBio and SOSV, Ten63 pushes boundaries in precision oncology and beyond, potentially reshaping how pharma tackles evolutionary diseases and inspiring hybrid AI-computational pipelines industry-wide.[1][3]
Ten63 is poised to advance BEYOND toward clinical candidates, targeting oncology first while expanding to other diseases, with potential partnerships amplifying its trillion-molecule screening edge.[1][2][5] Trends like AI integration in pharma and supercomputing will propel growth, evolving its influence from niche innovator to key player in undruggable target breakthroughs. As it scales from its Durham base, expect momentum in licensing deals, validating its mission to redefine druggability for patients.
Key people at Ten63 Therapeutics.
Ten63 Therapeutics has raised $61.0M in total across 2 funding rounds.
Ten63 Therapeutics's investors include Bill & Melinda Gates Foundation, John Gustofson, Hatteras Venture Partners, Amplify Partners, Draper Associates, Intel Capital, KRM Interests LLC, Mayfield, Morpheus Ventures, SOSV, TenOneTen Ventures, Village Global.
Ten63 Therapeutics has raised $61.0M across 2 funding rounds. Most recently, it raised $45.0M Other Equity in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 19, 2026 | $45M Venture Round | Bill & Melinda Gates Foundation, John Gustofson | — | Announced |
| May 1, 2023 | $16M Series A | Hatteras Venture Partners | Amplify Partners, Draper Associates, Intel Capital, KRM Interests LLC, Mayfield, Morpheus Ventures, SOSV, TenOneTen Ventures, Village Global, XYZ Venture Capital, Alexandria Venture Investments, Draper Round Table, Sigma Group | Announced |